Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Kuykendall on Frontline Cytoreductive Therapies in Polycythemia Vera

October 21st 2023

Andrew Kuykendall, MD, discusses frontline cytoreductive treatment options for patients with polycythemia vera.

Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and Anemia

October 20th 2023

Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.

Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm

October 19th 2023

Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.

Dr Zhou on the Use of Combination Therapies in Myelofibrosis

October 13th 2023

Amy W. Zhou, MD, discusses combination therapies with ruxolitinib that may contribute to the treatment paradigm for patients with myelofibrosis, highlighting the importance of continued research with phase 3 confirmatory trials for patients with this disease.

Bexmarilimab Plus SOC Continues to Elicit Responses in R/R AML and HMA-Refractory MDS

October 11th 2023

The addition of bexmarilimab to standard-of-care azacitidine or azacitidine plus venetoclax continued to elicit responses in patients with relapsed or refractory acute myeloid leukemia and those with myelodysplastic syndrome who were refractory to hypomethylating agents.

Dr Parrondo on the Clinical Benefit of Momelotinib on Anemia in Myelofibrosis

October 6th 2023

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.

EMA Validates MAA for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

October 3rd 2023

The European Medicines Agency has validated the marketing authorization application for the use of imetelstat in the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome.

Dr Zhou on the Evaluation of Combination Therapies With Ruxolitinib in Myelofibrosis

September 28th 2023

Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26th 2023

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Investigation of Novel Management Strategies Continues to Mitigate Disease-Related Toxicities Across Hematologic Malignancies

September 26th 2023

Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis.

Future Perspectives in the Treatment of Polycythemia Vera

September 22nd 2023

John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.

MWTX-003 Wins FDA Fast Track Designation for Polycythemia Vera

September 21st 2023

The FDA has granted fast track designation to the investigational, anti-TMPRSS6 monoclonal antibody, MWTX-003 (DISC-3405), for use in the treatment of patients with polycythemia vera, according to an announcement from Disc Medicine, Inc.

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21st 2023

Uwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s investigation in patients with lower-risk MDS who are transfusion independent.

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

September 19th 2023

Uwe Platzbecker, MD, discusses how the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.

Dr Kuykendall on the FDA Approval of Momelotinib in Myelofibrosis

September 15th 2023

Andrew Kuykendall, MD, discusses the significance of the FDA approval of momelotinib in patients with myelofibrosis.

FDA Approves Momelotinib for Myelofibrosis With Anemia

September 15th 2023

The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.

Ruxolitinib in the Treatment of PV

September 15th 2023

Key opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.

Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

September 15th 2023

Joe Scandura, MD, PhD, explains how a patient with polycythemia vera and driver mutations responds to interferon treatment.

NICE Recommends Ruxolitinib for Hydroxycaramide/Hydroxyurea Resistant or Intolerant Polycythemia Vera

September 14th 2023

The National Institute for Health and Care Excellence has published its Final Draft Guidance recommending the use of ruxolitinib as treatment for eligible patients in England and Wales with polycythemia vera that is resistant or intolerant to hydroxycarbamide/hydroxyurea.

JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis

September 12th 2023

Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.